ACMJ
Anatolian Current Medical Journal

Anatolian Current Medical Journal (ACMJ) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

eISSN: 2718-0115
Creative Commons CC BY-NC-ND 4.0 International License.
EndNote Style

Submit Manuscript

Index
Original Article
Pan-immune inflammation value as a biomarker in ankylosing spondilitis and associated with disease activity
Abstract
Aims: Ankylosing spondylitis(AS) is the most common and characteristic form of Spondyloarthritis. The pan-immune inflammation value(PIV) is a marker obtained from complete blood count parameters, which has been used as an inflammatory and immune marker. In this study, we aimed to investigate the relationship between inflammation and disease activity in patients with AS and PIV.
Methods: In this prospective controlled study a total of 208 participants were included, consisting of 104 AS patients and 104 healthy controls. Complete blood count values, including neutrophils, monocytes, lymphocytes, platelets, and also C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), were measured in all participants. In AS group disease activity was assessed with Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). The AS group was divided into two subgroups based on BASDAI score: low disease activity(BASDAI score <4) and high disease activity(BASDAI score ?4).The pan-immune inflammation value of patients and the control group was calculated as neutrophil count × monocyte count × platelet count/lymphocyte count. Comparative analysis was performed between the two groups, and these values were also compared based on the BASDAI.
Results: The AS group exhibited statistically higher values of CRP, monocytes, and PIV compared to the control group (p<0.001 for all). Patients with BASDAI?4 had a statistically lower disease duration (p<0.001) and lymphocyte count (p:0.012) compared to those with BASDAI<4. Patients with BASDAI ? 4 had statistically higher values of CRP, ESR, neutrophils, platelets, and PIV compared to those with BASDAI<4 (p<0.001, p<0.001, p<0.001, p:0.008, p<0.001 respectively). Strong positive correlation was found between PIV and BASDAI (rho=0.790; p<0.001), moderate positive correlation with PIV and CRP (rho=0.467; p<0.001) and also positive correlation was found between PIV and ESR (rho=0.326; p<0.001). The specificity and sensitivity of PIV using a cutoff value of >309,2 were 80.0% and 86.0% respectively, for the active group.
Conclusion: Since the parameters comprising PIV are obtained from a complete blood count, it provides an advantage for its use as a simple and cost-effective marker in ankylosing spondylitis patients. In our study, we demonstrated that PIV is sensitive and specific in differentiating disease activity in patients with ankylosing spondylitis from healthy individuals and associated with disease activity.

Keywords : Ankylosing spondylitis, pan-immune-inflammation value, disease activity

Download Article


1. Stolwijk C, Essers I, van Tubergen A, et al. The epidemiologyof extra-articular manifestations in ankylosing spondylitis:a population-based matched cohort study. Ann Rheum Dis.2015;74(7):1373-1378. doi: 10.1136/annrheumdis-2014-205253
2. Lee JH, Choi M, Rim THT, Lee SC, Lee CS. Clinicalcharacteristics and prognostic factors in ankylosing spondylitisassociated uveitis. Ocul Immunol Inflamm. 2019;27(1):64-69. doi:10.1080/09273948.2017.1359630
3. Mauro D, Thomas R, Guggino G, Lories R, Brown MA, CicciaF. Ankylosingspondylitis: an autoimmune or autoinflammatorydisease? Nat Rev Rheumatol. 2021;17(7):387-404. doi: 10.1038/s41584-021-00625-y
4. Poddubnyy D. Classification vs diagnostic criteria: thechallenge of diagnosing axial spondyloarthritis. Rheumatol.2020;59(Suppl4):iv6-iv17. doi: 10.1093/rheumatology/keaa250
5. Colglazier CL, Sutej PG. Laboratory testing in the rheumaticdiseases: a practical review. South Med J. 2005;98(2):185-191. doi:10.1097/01.SMJ.0000153572.22346.E9
6. Poddubnyy D, Haibel H, Listing J, et al. Baseline radiographicdamage, elevated acute-phase reactant levels, and cigarettesmoking status predict spinal radiographic progression in earlyaxial spondylarthritis. Arthritis Rheum. 2012;64(5):1388-1398.
7. Glintborg B, &Oslash;stergaard M, Krogh NS, Dreyer L, KristensenHL, Hetland ML. Predictors of treatment response and drugcontinuation in 842 patients with ankylosing spondylitistreated with anti-tumour necrosis factor: results from 8 years&rsquo;surveillance in the Danish nationwide DANBIO registry. AnnRheum Dis. 2010;69(11):2002-2008.
8. Mandaliya H, Jones M, Oldmeadow C, Nordman IIC.Prognosticbiomarkers in stage IV non-small cell lung cancer(NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte tomonocyte ratio (LMR), platelet to lymphocyte ratio (PLR) andadvanced lung cancer inflammation index (ALI). Transl LungCancer Res. 2019;8(6):886-889.
9. Kadihasanoglu M, Karabay E, Yucetas U, Erkan E, OzbekE. Relation between monocyteto high-density lipoproteincholesterol ratio and presence and severity of erectile dysfunction.Aktuelle Urol. 2018;7(03):256-261.
10. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentationrate and C-reactive protein in ankylosing spondylitis: a literaturereview. J Rheumatol. 1999;26(4):966-970.
11. Elyan M, Khan MA. Diagnosing ankylosing spondylitis. JRheumatol Suppl. 2006;78:12-23.
12. Wu J, Yan L, Chai K. Systemic immune-inflammation indexis associated with disease activity in patients with ankylosingspondylitis. J Clin Lab Anal. 2021;35(9):e23964. doi: 10.1002/jcla.23964
13. Ulutaş F, &Ccedil;obankara V. Pan-immune-inflammation value(PIIV) in lupus nephritis. Med Sci Discov. 2023;10(4):234-238. doi:10.36472/msd.v10i4.918
14. Baba Y, Nakagawa S, Toihata T, et al. Pan-immune-inflammationvalue and prognosis in patients with esophageal cancer. AnnSurg Open. 2022;3(1):e113.
15. Yang XC, Liu H, Liu DC, Tong C, Liang XW, Chen RH. Prognosticvalue of pan-immune-inflammation value in colorectal cancerpatients: a systematic review and meta-analysis. Front Oncol.2022;12:1036890
16. Truffi M, Sottotetti F, Gafni N, et al. Prognostic potential of immuneinflammatory biomarkers in breast cancer patients treated withneoadjuvant chemotherapy. Cancers. 2022;14(21):5287.
17. Lin F, Zhang LP, Xie SY, et al. Pan-immune-inflammation value:a new prognostic index in operative breast cancer. Front Oncol.2022;12:830138
18. Van der Heijde D, Lie E, Kvien TK, et al. Assessment ofSpondyloArthritis international Society (ASAS). ASDAS, ahighly discriminatory ASAS-endorsed disease activity scorein patients with ankylosing spondylitis. Ann Rheum Dis.2009;68(12):1811-1818. doi:10.1136/ard.2008.100826
19. Van der Heijde D, Sieper J, Maksymowych WP, et al; Assessmentof SpondyloArthritis International Society. 2010 update of theinternational ASAS recommendations for the use of anti-TNFagents in patients with axial spondyloarthritis. Ann Rheum Dis.2011;70(6):905-908. doi: 10.1136/ard.2011.151563
20. Braun J, Pham T, Sieper J, et al. International ASAS consensusstatement for the use of anti-tumour necrosis factor agents inpatients with ankylosing spondylitis. Ann Rheum Dis. 2003;62(9):817-824.
21. Kayhan S, Aydın Isak O. The significance of pan-immuneinflammation value and systemic immune inflammation index incolorectal cancer screening. Turk J Clin Lab. 2021;12(3):273-277
22. Wiley. CMT Level II 2018: Theory and Analysis. John Wiley &amp;Sons:2018.
23. Wright GC, Kaine J, Deodhar A. Understanding differencesbetween men and women with axial spondyloarthritis. SeminArthritis Rheum. 2020;50(4):687-694. doi:10.1016/ j.semarthrit.2020.05.005
24. Mantovani A, Cassatella MA, Costantini C, Jaillon S.Neutrophils in the activation and regulation of innate andadaptive immunity. Nat Rev Immunol. 2011;11(8):519-531.doi:10.1038/nri3024
25. Wu J, Yan L, Chai K. Systemic immune-inflammation indexis associated with disease activity in patients with ankylosingspondylitis. J Clin Lab Anal. 2021;35(9):e23964. doi: 10.1002/jcla.23964
26. Shanshan Xu, Yubo Ma, Meng Wu, et al. Neutrophil lymphocyteratio in patients with ankylosing spondylitis: a systematicreview and meta-analysis. Modern Rheumatol. 2020;30(1):141-148. doi.org/10.1080/14397595.2018.1564165
27. Boyraz I, Ko&ccedil; B, Boyacı A, Tutoğlu A, Sarman H, Ozkan H.Ratio of neutrophil/lymphocyte and platelet/lymphocyte inpatient with ankylosing spondylitis that are treating with anti-TNF. Int J Clin Exp Med. 2014;7(9):2912-2915.
28. Doğan M, Boyacıoğlu Z, Doğan AG. Evaluation of neutrophyl/lymphocyte ratio, platelet/lymphocyte ratio and mean plateletvolume according to the disease activity index in patients ofankylosing spondylitis. J Health Sci Med. 2022;5(1):247-251.
29. Spoorenberg A, van der Heijde D, de Klerk E, et al. Relativevalue of erythrocyte sedimentation rate and C-reactive proteinin assessment of disease activity in ankylosing spondylitis. JRheumatol. 1999;26(4):980-984.
30. Ruof J, Stucki G. Validity aspects of erythrocyte sedimentationrate and C-reactive protein in ankylosing spondylitis: aliterature review. J Rheumatol. 1999;26(4):966-970.
31. Baba Y, Nakagawa S, Toihata T, et al. Pan-immune-inflammationvalue and prognosis in patients with esophageal cancer. Ann SurgOpen. 2021;3(1):e113. doi:10.1097/AS9.0000000000000113
32. Truffi M, Sottotetti F, Gafni N, et al. Prognostic potentialof immune inflammatory biomarkers in breast cancerpatients treated with neoadjuvant chemotherapy. Cancers.2022;14(21):5287. doi:10.3390/cancers14215287
33. Guven DC, Sahin TK, Erul E, Kilickap S, Gambichler T, AksoyS. The association between the pan-immune-inflammation valueand cancer prognosis: a systematic review and meta-analysis.Cancers. 2022;14(11):2675. doi:10.3390/cancers14112675
34. Zhang F, Li L, Wu X, et al. Pan-immune-inflammation value isassociated with poor prognosis in patients undergoing peritonealdialysis. Ren Fail. 2023;45(1):2158103. doi:10.1080/0886022X.2022.2158103
35. Kazan DE, Kazan S. Systemic immune inflammation indexand pan-immune inflammation value as prognostic markers inpatients with idiopathic low and moderate risk membranousnephropathy. Eur Rev Med Pharmacol Sci. 2023;27(2):642-648.doi:10.26355/eurrev_202301_31065
36. Rudwaleit M, Haibel H, Baraliakos X, et al. The early diseasestage in axial spondylarthritis: results from the GermanSpondyloarthritis Inception Cohort. J Am College Rheumatol.2009;60(3):717-727.
37. Tutan D, Doğan AG. Pan-immune-inflammation index as abiomarker for rheumatoid arthritis progression and diagnosis.Cureus. 2023;15(10):e46609
38. Lee LE, Ahn SS, Pyo JY, Song JJ, Park YB, Lee SW. Pan-immune-inflammation value at diagnosis independently predicts all-causemortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis. Clin Exp Rheumatol. 2021;39(2):S88-S93.
39. Ulutaş F, Aydın M. Pan-immune-inflammation value in FMFpatients. Med Sci Discov. 2023;10(6):364-367.
Article available in :
Volume 6, Issue 1, 2024
Page : 48-54
https://doi.org/10.38053/acmj.1390868
Article Information
Received : 17 Kas 2023
Accepted : 10 Ara 2023
Published : 15 Oca 2024
Corresponding Author :

Ülkem Şen Uzeli: Department of Internal Medicine, Hitit University Erol Olçok Training and Research Hospital, Çorum, Turkiye

[email protected]
Citation : Şen Uzeli Ü, Başaran PÖ. Pan-immune inflammation value as a biomarker in ankylosing spondilitis and associated with disease activity. Anatolian Curr Med J. 2024;6(1):48-54.

Read: 46
Cited: 0
Download : 38
_Footer